R. Garg

发表

Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine.

S. Yusuf, B. Pitt, M. Packer, 1993, Journal of the American College of Cardiology.

Regional variation in ischemic heart disease incidence.

J. Madans, J. C. Kleinman, R. Garg, 1992, Journal of clinical epidemiology.

Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure.

M. Gheorghiade, S. Jafri, R. Garg, 1998, Progress in cardiovascular diseases.

Current and ongoing randomized trials in heart failure and left ventricular dysfunction.

S. Yusuf, R. Garg, 1993, Journal of the American College of Cardiology.

Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure.

S. Yusuf, R. Gorlin, P. Held, 1992, The American journal of cardiology.

Racial differences in outcome and treatment effect in congestive heart failure.

S. Yusuf, J. Wittes, J. Mathew, 2005, American heart journal.

Overview of the DIG trial.

S. Yusuf, N. Geller, W. Williford, 2003, Controlled clinical trials.

The use of regional coordinating centers in large clinical trials: the DIG trial.

D. Egan, J. Collins, R. Garg, 2003, Controlled clinical trials.

The role of the data coordinating center in the DIG trial.

S. Yusuf, W. Williford, D. Egan, 2003, Controlled clinical trials.

Lessons learned from the DIG trial.

S. Yusuf, N. Geller, J. Mathew, 2003, Controlled clinical trials.

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

S. Yusuf, S. Yusuf, R. Garg, 1995, JAMA.

Alcohol Consumption and Risk of Ischemic Heart Disease in Women

D. Wagener, J. Madans, R. Garg, 1993, Archives of internal medicine.

The role of the data coordinating center in the IRB review and approval process: the DIG trial experience.

K. Teo, W. Williford, J. Collins, 2003, Controlled clinical trials.

Design, results, and interpretation of randomized, controlled trials in congestive heart failure and left ventricular dysfunction

S. Yusuf, R. Garg, 1993 .

The effect of digoxin on mortality and morbidity in patients with heart failure.

E. J. Brown, Hack, D. M. Barr, 1997, The New England journal of medicine.

Cardiovascular Calcification in Systemic Diseases

P. Raggi, R. Garg, 2021, Cardiovascular Calcification.

Cardiac glycosides in the next millennium.

R. Kelly, P. Hauptman, R. Garg, 1999, Progress in cardiovascular diseases.

The Relationship Between Cardiothoracic Ratio and Left Ventricular Ejection Fraction in Congestive Heart Failure

R M Lang, J. Fleg, R. Lang, 1998 .

The effect of digoxin on the quality of life in patients with heart failure.

S. Czajkowski, S. Hunsberger, D. Egan, 2003, Journal of cardiac failure.

Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure

S. Yusuf, Salim Yusuf, R Garg, 1995 .

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

R. Rossaint, E. Abraham, P. Laterre, 2005, The New England journal of medicine.

Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995.

B. Psaty, J. Gottdiener, B. Pitt, 1998, Archives of internal medicine.

Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure.

D. M. Barr, D. F. Hughes, R. Collins, 1996, Controlled clinical trials.

Randomized trials to assess the long-term effects of therapies on angiographic end points.

S. Yusuf, R. Garg, 1991, Chest.

Prognosis in Congestive Heart Failure

S. Yusuf, M. Domanski, R. Garg, 1994 .

HEART FAILURE IN THE 1991S : EVOLUTION OF A MAJOR PUBLIC HEALTH PROBLEM INCARDIOVASCULAR MEDICINE

S. Yusuf, B. Pitt, M. Packer, 1993 .

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis

J. Vincent, A. Wheeler, X. Wittebole, 2006, Critical care.

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial *

G. Clermont, D. Angus, J. Dhainaut, 2004, Critical care medicine.

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis *

G. Bernard, D. Angus, L. Weissfeld, 2004, Critical care medicine.

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis

Mark D. Williams, D. Nelson, A. Sashegyi, 2005, Critical care.

Outcomes of cancer patients treated with drotrecogin alfa (activated) for severe sepsis.

D. Nelson, J. Leclerc, D. Joyce, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analyses by the Intention‐to‐Treat Principle in Randomized Trials and Databases

S. Yusuf, D. Zucker, R. Garg, 1991, Pacing and clinical electrophysiology : PACE.

Etiology and characteristics of congestive heart failure in blacks.

J. Mathew, R. Garg, L. Narra, 1996, The American journal of cardiology.

Usefulness of clinical information to distinguish patients with normal from those with low ejection fractions in heart failure.

E. Philbin, M. Silver, U. Thadani, 2002, The American journal of cardiology.

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.

D. Hunninghake, J. Kostis, K. Davis, 2000, JAMA.